Advances in the genetics of myasthenia gravis: insights from cutting-edge neuroscience research - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39845831/
Myasthenia gravis (MG) is an autoimmune disorder involving complex interactions between genetic and environmental factors. Genome-wide association studies (GWAS), transcriptome-wide association studies (TWAS), and other methods have identified multiple novel...
This review explores recent advances in myasthenia gravis genetics, highlighting susceptibility loci, epigenetic mechanisms, gene-environment interactions, and their implications for subtype-specific factors, diagnostics, prognostics, and biomarkers.
Nanodrug Delivery Systems for Myasthenia Gravis: Advances and Perspectives - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38794313/
Myasthenia gravis (MG) is a rare chronic autoimmune disease caused by the production of autoantibodies against the postsynaptic membrane receptors present at the neuromuscular junction. This condition is characterized by...
Myasthenia gravis involves immune dysregulation, mitochondrial dysfunction, and ferroptosis. Nanomedicines targeting immunomodulation, mitochondrial restoration, and ferroptosis inhibition show promise as potential therapies for this autoimmune disease.
Aging and infectious diseases in myasthenia gravis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39671879/
Over the past 120 years, mortality associated with myasthenia gravis (MG) has steadily decreased while the incidence of MG has increased. While mortality due to MG has been ≤5 %...
Myasthenia gravis prevalence has risen due to aging, immunosenescence, and better diagnostics. Patients, especially elderly, face higher infection risks, worsened by immunosuppressive therapies, necessitating vigilant infection monitoring and treatment.
Exploring the depths of IgG4: insights into autoimmunity and novel treatments - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38698867/
IgG4 subclass antibodies represent the rarest subclass of IgG antibodies, comprising only 3-5% of antibodies circulating in the bloodstream. These antibodies possess unique structural features, notably their ability to undergo...
IgG4 antibodies, comprising 3-5% of circulating antibodies, play key roles in autoimmune diseases like IgG4-AID and IgG4-RD. These conditions respond to anti-CD20-mediated B cell depletion therapy, highlighting potential therapeutic strategies.
Targeting autoimmune mechanisms by precision medicine in Myasthenia Gravis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38903526/
Myasthenia Gravis (MG) is a chronic disabling autoimmune disease caused by autoantibodies to the neuromuscular junction (NMJ), characterized clinically by fluctuating weakness and early fatigability of ocular, skeletal and bulbar...
Myasthenia Gravis is a heterogeneous autoimmune disorder requiring lifelong immunosuppression. Precision medicine, targeting B cells, complement, and antibody recycling, offers promising therapeutic advancements, emphasizing patient stratification through genetic and molecular biomarkers for optimized treatment.